DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, provisions relating to cargo transport. Federal policy, and potential solutions, relating to supply chain disruptions resulting from Chinas implementation of sanitary and phytosanitary (SPS) measures in violation of the U.S.-China Phase One Deal and Chinas World Trade Organization obligations. Healthcare issues related to clinical laboratories;

H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;

Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;

Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;

S. 610, the Protecting Medicare and American Farmers from Sequester Cuts Act, provisions relating to delays in data collection and rate changes pertinent to the Medicare Clinical Laboratory Fee Schedule, mitigation of the Medicare sequester and rate changes pertinent to the Medicare Physician Fee Schedule, and suspension of certain statutory pay-as-you-go requirements;

S. 701, the Allergy Testing Access Act, provisions relating to Medicare coverage of certain allergy tests;

H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services;

H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories;

Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;

H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing;

S. 1605, the National Defense Authorization Act for Fiscal Year 2022, provisions relating to TRICARE coverage of preconception and prenatal carrier screening;

H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; and

Federal policy relating to use of pharmacogenetic information, including a discussion draft of the Right Drug Dose Now Act.
TRA - Transportation TRD - Trade (domestic/foreign) HCR - Health Issues
11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 22 - U.S. Trade Representative (USTR) 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 22 - U.S. Trade Representative (USTR) 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 22 - U.S. Trade Representative (USTR)
LABORATORY CORPORATION OF AMERICA HOLDINGS
531 South Spring Street, Burlington, NC, 27215, US
DONALD HORTON KATHERINE PREGEL DONALD HORTON KATHERINE PREGEL DONALD HORTON KATHERINE PREGEL